Research Study

A Phase 2, Single Arm, Open Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor Positive, Triple Negative Breast Cancer
Principal Investigator 
Karen A. Gelmon

Overview

Body Locations and Systems 
Breast Cancer
Disorders and Conditions 
ClinicalTrials.gov# 
NCT01889238
Status 
Closed to Recruitment
Study Start/End 
Dec 9, 2013 to Dec 1, 2016
Locations 
St. Paul's Hospital, Vancouver General Hospital
Name/Title 
Cheryl Carrasco, Study Coordinator
Phone 
604-877-6000 ext.672698
Purpose of Study 

The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.